Zürich16°Clear
Filtrato per argomento
Ultime notizie e aggiornamenti Alzheimer's dalla Svizzera. Articoli curati dall'IA che coprono argomenti Alzheimer's.
← Mostra tutte le notizieHealthcare
Swiss medicines regulator Swissmedic has approved Kisunla (donanemab) for early-stage Alzheimer's but not Leqembi (lecanemab), a drug already available in over 50 countries. The decision leaves Swiss patients with fewer advanced treatment options compared to many other nations.
7 months ago · 1 source
Health
In a landmark decision, Swissmedic has authorized Donanemab, the first drug proven to slow the cognitive decline associated with Alzheimer's disease. The approval offers new hope for patients in the early stages of the illness, though questions surrounding health insurance coverage remain.
SWI swissinfo.ch
Health
In a landmark decision, Swiss medicines regulator Swissmedic has authorised Donanemab, the first drug in Switzerland that can slow the cognitive decline associated with early-stage Alzheimer's disease.
SWI swissinfo.ch
Health
Swissmedic, the national regulator, has approved Donanemab (Kisunla), the first drug in Switzerland that can slow the progression of Alzheimer's disease in patients at an early stage. While patient groups welcome the news, questions remain about whether health insurance will cover the costs of the treatment.
SWI swissinfo.ch
